World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
108
Citations
56985
World Ranking
960
National Ranking
585

Medicine

D-Index
110
Citations
58777
World Ranking
5455
National Ranking
2938

Cheryl L. Willman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Cheryl L. Willman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 409 publications — 40th percentile

40% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Cheryl L. Willman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Cheryl L. Willman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 2017 - Fellow, National Academy of Inventors

Overview

Cheryl L. Willman is affiliated with the University of New Mexico in the United States. Their research is primarily situated within the field of Medicine, with a strong emphasis on Public Health, Environmental and Occupational Health, Hematology, Genetics, Cancer Research, and Pediatrics, Perinatology and Child Health.

Their scholarly work focuses notably on several key topics:

  • Acute Lymphoblastic Leukemia research
  • Cancer Genomics and Diagnostics
  • Acute Myeloid Leukemia Research
  • Childhood Cancer Survivors' Quality of Life
  • Advances in Oncology and Radiotherapy
  • Health and Medical Research Impacts
  • Chronic Myeloid Leukemia Treatments

Cheryl L. Willman has contributed to numerous publications, with notable recent papers including:

  • The genomic landscape of pediatric acute lymphoblastic leukemia, 2022, Nature Genetics
  • Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults, 2024, New England Journal of Medicine
  • Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL, 2021, Blood
  • Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities, 2020, Clinical Cancer Research
  • Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial, 2022, Blood

Their work appears frequently in well-established scientific venues, including:

  • Blood
  • Journal of Clinical Oncology
  • Cancer Research
  • Cancer Epidemiology Biomarkers & Prevention
  • Clinical Cancer Research

Cheryl L. Willman has collaborated extensively with other researchers. The most frequent coauthors include:

  • Charles G. Mullighan
  • Brent L. Wood
  • Kathryn G. Roberts
  • Richard C. Harvey
  • Harry P. Erba

In recognition of their contributions, Cheryl L. Willman was named a Fellow of the National Academy of Inventors in 2017.

Best Publications

  • Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

    Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner

  • Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

    Marilyn L. Slovak;Kenneth J. Kopecky;Peter A. Cassileth;David H. Harrington

  • Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

    Charles G Mullighan;Xiaoping Su;Jinghui Zhang;Ina Radtke

  • Age and acute myeloid leukemia

    Frederick R Appelbaum;Holly M Gundacker;David R Head;Marilyn L Slovak

  • Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

    K. G. Roberts;Y. Li;D. Payne-Turner;R. C. Harvey

  • Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.

    C L Willman;L Busque;B B Griffith;B E Favara

  • All-trans-Retinoic Acid in Acute Promyelocytic Leukemia

    Martin S. Tallman;Janet W. Andersen;Charles A. Schiffer;Frederick R. Appelbaum

  • Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

    Catherine P. Leith;Kenneth J. Kopecky;John Godwin;Thomas McConnell

  • Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia

    W.-J. Song;M. G. Sullivan;R. D. Legare;S. Hutchings

  • The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers

    Carlee E. Ashley;Carlee E. Ashley;Eric C. Carnes;Genevieve K. Phillips;David P Padilla

  • Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.

    K. E. Noonan;C. Beck;T. A. Holzmayer;J. E. Chin

  • The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia

    Yu Liu;John Easton;Ying Shao;Jamie Maciaszek

  • Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

    Michael J. Borowitz;Meenakshi Devidas;Stephen P. Hunger;W. Paul Bowman;W. Paul Bowman

  • Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study

    Catherine P. Leith;Kenneth J. Kopecky;I-Ming Chen;Lisette Eijdems

  • Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

    Kathryn G. Roberts;Ryan D. Morin;Jinghui Zhang;Martin Hirst

  • Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission

    Peter A. Cassileth;David P. Harrington;Frederick R. Appelbaum;Hillard M. Lazarus

  • Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

    Richard C. Harvey;Richard C. Harvey;Charles G. Mullighan;I-Ming Chen;I-Ming Chen;Walker Wharton

  • JAK mutations in high-risk childhood acute lymphoblastic leukemia.

    Charles G. Mullighan;Jinghui Zhang;Richard C. Harvey;J. Racquel Collins-Underwood

  • Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

    Charles G Mullighan;J Racquel Collins-Underwood;Letha A A Phillips;Michael G Loudin

  • Gene expression changes associated with progression and response in chronic myeloid leukemia

    Jerald P. Radich;Hongyue Dai;Mao Mao;Vivian Oehler

Frequent Co-Authors

Stephen P. Hunger
Stephen P. Hunger University of Pennsylvania
William L. Carroll
William L. Carroll New York University
Meenakshi Devidas
Meenakshi Devidas St. Jude Children's Research Hospital
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
Mignon L. Loh
Mignon L. Loh University of California, San Francisco
Charles G. Mullighan
Charles G. Mullighan St. Jude Children's Research Hospital
Naomi J. Winick
Naomi J. Winick The University of Texas Southwestern Medical Center
Michael J. Borowitz
Michael J. Borowitz Johns Hopkins University
Elizabeth A. Raetz
Elizabeth A. Raetz New York University
Andrew J. Carroll
Andrew J. Carroll University of Alabama at Birmingham

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine students and professionals often explore online degree options that offer flexibility and career advancement. The growing demand for healthcare leaders has led many to pursue cahme accredited online mha programs, which focus on healthcare administration and management skills.

For registered nurses aiming to enhance their credentials without the commitment of in-person training, several online rn to bsn programs without clinicals provide a convenient path to earning a bachelor's degree in nursing.

Nurses seeking advanced clinical or leadership roles may consider doctoral options. Aspiring nurse practitioners can choose between 1 year dnp program online offerings for accelerated progression, or explore a variety of dnp programs tailored for working professionals.

These pathways support career growth and specialization, making it easier to balance study, work, and personal commitments while advancing in the healthcare field.

Best Scientists Citing Cheryl L. Willman

Trending Scientists

Recently Published Articles